Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation

Yuriko Morita, Yuji Heike, Mami Kawakami, Osamu Miura, Shin Ichi Nakatsuka, Michiko Ebisawa, Shin Ichiro Mori, Ryuji Tanosaki, Takahiro Fukuda, Sung W. Kim, Kensei Tobinai, Yoichi Takaue

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Donor-derived cytotoxic T lymphocytes (CTL) that respond to tumor antigens emerge after hematopoietic stem cell transplantation (HSCT), particularly in association with the status of immune recovery. To analyze the frequency of CTL against PR1, PRAME and WT1 after HSCT, a tetramer-based analysis was performed in 97 samples taken from 35 patients (9 AML, 11 MDS, 2 CML, 4 ALL, 7 lymphoma and 2 renal cell carcinoma [RCC]) with the HLA-A02 phenotype. Regarding PR1, only 1 sample showed the presence of tetramer-positive cells (0.04%/lymphocyte). Similarly, in PRAME, only 10 of 97 samples were sporadically positive with low titers. For WT1, positive results were detected in 39 of 97 samples and 7 (2 CML, 1 ALL, 2 lymphoma and 2 RCC) patients clearly showed positive results more than once. On the basis of these results, we performed serial analyses of WT1-specific CTL during the clinical course in 2 patients with RCC, who underwent HSCT with a reduced-intensity regimen, to examine the precise correlation between the kinetics of CTL, the occurrence of GVHD and the observed clinical response. A higher positive rate for WT1-speciflc CTL and a correlation with the clinical response suggest that WT1 may be a useful antigen for a wider monitoring application.

Original languageEnglish
Pages (from-to)1360-1367
Number of pages8
JournalInternational Journal of Cancer
Volume119
Issue number6
DOIs
Publication statusPublished - 2006 Sep 15
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Cytotoxic T-Lymphocytes
Renal Cell Carcinoma
Lymphoma
Neoplasm Antigens
varespladib methyl
Tissue Donors
Lymphocytes
Phenotype
Antigens

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Cytotoxic T lymphocytes
  • Renal cell carcinoma
  • WT1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Morita, Y., Heike, Y., Kawakami, M., Miura, O., Nakatsuka, S. I., Ebisawa, M., ... Takaue, Y. (2006). Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. International Journal of Cancer, 119(6), 1360-1367. https://doi.org/10.1002/ijc.21960

Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. / Morita, Yuriko; Heike, Yuji; Kawakami, Mami; Miura, Osamu; Nakatsuka, Shin Ichi; Ebisawa, Michiko; Mori, Shin Ichiro; Tanosaki, Ryuji; Fukuda, Takahiro; Kim, Sung W.; Tobinai, Kensei; Takaue, Yoichi.

In: International Journal of Cancer, Vol. 119, No. 6, 15.09.2006, p. 1360-1367.

Research output: Contribution to journalArticle

Morita, Y, Heike, Y, Kawakami, M, Miura, O, Nakatsuka, SI, Ebisawa, M, Mori, SI, Tanosaki, R, Fukuda, T, Kim, SW, Tobinai, K & Takaue, Y 2006, 'Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation', International Journal of Cancer, vol. 119, no. 6, pp. 1360-1367. https://doi.org/10.1002/ijc.21960
Morita, Yuriko ; Heike, Yuji ; Kawakami, Mami ; Miura, Osamu ; Nakatsuka, Shin Ichi ; Ebisawa, Michiko ; Mori, Shin Ichiro ; Tanosaki, Ryuji ; Fukuda, Takahiro ; Kim, Sung W. ; Tobinai, Kensei ; Takaue, Yoichi. / Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. In: International Journal of Cancer. 2006 ; Vol. 119, No. 6. pp. 1360-1367.
@article{6d947331fff742e493471429a2114e01,
title = "Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation",
abstract = "Donor-derived cytotoxic T lymphocytes (CTL) that respond to tumor antigens emerge after hematopoietic stem cell transplantation (HSCT), particularly in association with the status of immune recovery. To analyze the frequency of CTL against PR1, PRAME and WT1 after HSCT, a tetramer-based analysis was performed in 97 samples taken from 35 patients (9 AML, 11 MDS, 2 CML, 4 ALL, 7 lymphoma and 2 renal cell carcinoma [RCC]) with the HLA-A02 phenotype. Regarding PR1, only 1 sample showed the presence of tetramer-positive cells (0.04{\%}/lymphocyte). Similarly, in PRAME, only 10 of 97 samples were sporadically positive with low titers. For WT1, positive results were detected in 39 of 97 samples and 7 (2 CML, 1 ALL, 2 lymphoma and 2 RCC) patients clearly showed positive results more than once. On the basis of these results, we performed serial analyses of WT1-specific CTL during the clinical course in 2 patients with RCC, who underwent HSCT with a reduced-intensity regimen, to examine the precise correlation between the kinetics of CTL, the occurrence of GVHD and the observed clinical response. A higher positive rate for WT1-speciflc CTL and a correlation with the clinical response suggest that WT1 may be a useful antigen for a wider monitoring application.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Cytotoxic T lymphocytes, Renal cell carcinoma, WT1",
author = "Yuriko Morita and Yuji Heike and Mami Kawakami and Osamu Miura and Nakatsuka, {Shin Ichi} and Michiko Ebisawa and Mori, {Shin Ichiro} and Ryuji Tanosaki and Takahiro Fukuda and Kim, {Sung W.} and Kensei Tobinai and Yoichi Takaue",
year = "2006",
month = "9",
day = "15",
doi = "10.1002/ijc.21960",
language = "English",
volume = "119",
pages = "1360--1367",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation

AU - Morita, Yuriko

AU - Heike, Yuji

AU - Kawakami, Mami

AU - Miura, Osamu

AU - Nakatsuka, Shin Ichi

AU - Ebisawa, Michiko

AU - Mori, Shin Ichiro

AU - Tanosaki, Ryuji

AU - Fukuda, Takahiro

AU - Kim, Sung W.

AU - Tobinai, Kensei

AU - Takaue, Yoichi

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Donor-derived cytotoxic T lymphocytes (CTL) that respond to tumor antigens emerge after hematopoietic stem cell transplantation (HSCT), particularly in association with the status of immune recovery. To analyze the frequency of CTL against PR1, PRAME and WT1 after HSCT, a tetramer-based analysis was performed in 97 samples taken from 35 patients (9 AML, 11 MDS, 2 CML, 4 ALL, 7 lymphoma and 2 renal cell carcinoma [RCC]) with the HLA-A02 phenotype. Regarding PR1, only 1 sample showed the presence of tetramer-positive cells (0.04%/lymphocyte). Similarly, in PRAME, only 10 of 97 samples were sporadically positive with low titers. For WT1, positive results were detected in 39 of 97 samples and 7 (2 CML, 1 ALL, 2 lymphoma and 2 RCC) patients clearly showed positive results more than once. On the basis of these results, we performed serial analyses of WT1-specific CTL during the clinical course in 2 patients with RCC, who underwent HSCT with a reduced-intensity regimen, to examine the precise correlation between the kinetics of CTL, the occurrence of GVHD and the observed clinical response. A higher positive rate for WT1-speciflc CTL and a correlation with the clinical response suggest that WT1 may be a useful antigen for a wider monitoring application.

AB - Donor-derived cytotoxic T lymphocytes (CTL) that respond to tumor antigens emerge after hematopoietic stem cell transplantation (HSCT), particularly in association with the status of immune recovery. To analyze the frequency of CTL against PR1, PRAME and WT1 after HSCT, a tetramer-based analysis was performed in 97 samples taken from 35 patients (9 AML, 11 MDS, 2 CML, 4 ALL, 7 lymphoma and 2 renal cell carcinoma [RCC]) with the HLA-A02 phenotype. Regarding PR1, only 1 sample showed the presence of tetramer-positive cells (0.04%/lymphocyte). Similarly, in PRAME, only 10 of 97 samples were sporadically positive with low titers. For WT1, positive results were detected in 39 of 97 samples and 7 (2 CML, 1 ALL, 2 lymphoma and 2 RCC) patients clearly showed positive results more than once. On the basis of these results, we performed serial analyses of WT1-specific CTL during the clinical course in 2 patients with RCC, who underwent HSCT with a reduced-intensity regimen, to examine the precise correlation between the kinetics of CTL, the occurrence of GVHD and the observed clinical response. A higher positive rate for WT1-speciflc CTL and a correlation with the clinical response suggest that WT1 may be a useful antigen for a wider monitoring application.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Cytotoxic T lymphocytes

KW - Renal cell carcinoma

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=33747457693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747457693&partnerID=8YFLogxK

U2 - 10.1002/ijc.21960

DO - 10.1002/ijc.21960

M3 - Article

C2 - 16596644

AN - SCOPUS:33747457693

VL - 119

SP - 1360

EP - 1367

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -